Citable filing context
BIIB's research view summarizes recent SEC filing context, starting with earnings from Jul 29, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 29, 2026 | earnings | Biogen reported Q2 2026 total revenue of $2.7 billion, a 3% increase year-over-year. |
| Jul 1, 2026 | guidance_update | Biogen expects Q2 2026 results to include $164 million in acquired in-process R&D and milestone expenses. |
| Jun 10, 2026 | other | Biogen Inc. reported the results of its 2026 Annual Meeting of Stockholders, including the election of ten directors. |
| Jul 29, 2026 | Guidance: non_gaap_diluted_eps | 12.00 to 13.00 |
| Jul 29, 2026 | Guidance: rd_and_sga_expense | 2650.00 to 2700.00 |
| Jul 29, 2026 | Guidance: revenue | not reported to not reported |
| Jul 29, 2026 | mda_quarterly | Biogen’s financial performance for the second quarter of 2026 was defined by the $5.3 billion acquisition of Apellis Pharmaceuticals, which added specialized immunology products SYFOVRE (geographic atrophy) and EMPAVELI (PNH and rare kidney diseases) to its portfolio. While total revenue grew 3.4% to $2.74 billion, net income fell significantly to $97.5 million from $634.8 million in the prior-year period, largely due to a 36.9% surge in total costs and expenses. This increase was driven by integration-related restructuring charges, higher R&D spending on clinical trials for felzartamab, salanersen, and litifilimab, and amortization of acquired inventory fair value step-ups. The company’s core Multiple Sclerosis (MS) franchise continues to face headwinds, with global MS revenue declining 13% to $963.3 million. This was primarily attributed to a 53% drop in TECFIDERA revenue due to generic competition in Europe and a broader patient transition toward higher-efficacy therapies. Conversely, the Rare Disease segment grew 10.8% to $601.7 million, supported by the launch of SKYCLARYS and QALSODY. Biogen also continues to co-commercialize LEQEMBI with Eisai, reporting $63.7 million in collaboration revenue. Management remains focused on navigating global tariff uncertainties and potential impacts from U.S. drug pricing reforms under the Inflation Reduction Act. |
| Apr 29, 2026 | mda_quarterly | Biogen’s financial performance for the first quarter of 2026 reflects a transition toward new growth drivers as its legacy Multiple Sclerosis (MS) franchise faces continued pressure. Total revenue grew 1.9% to $2.48 billion, supported by the launch of new products and collaborations. MS revenue remains challenged, with TECFIDERA sales declining 46.9% due to generic competition, though this was partially offset by growth in TYSABRI and VUMERITY. Key growth initiatives center on rare diseases and specialized immunology. The company is expanding its portfolio through the proposed $5.6 billion acquisition of Apellis Pharmaceuticals, which adds SYFOVRE (geographic atrophy) and EMPAVELI (PNH/kidney diseases). Additionally, Biogen is consolidating global rights to felzartamab through a new agreement with TJ Biopharma. Alzheimer’s collaboration revenue from LEQEMBI reached $59.5 million, reflecting continued global uptake. Operating expenses were impacted by a 24.2% increase in R&D, driven by clinical trial investments in felzartamab, litifilimab, and SKYCLARYS inventory step-up amortization. While the company maintains a strong liquidity position with $4.7 billion in cash and marketable securities, it faces ongoing risks from the U.S. Inflation Reduction Act, global tariff volatility, and potential biosimilar competition for TYSABRI. Management continues to prioritize pipeline advancement and strategic acquisitions to offset the decline of mature assets. |
Source: SEC EDGAR filing text and events; period Jul 29, 2026; filed Jul 29, 2026.
BIIB company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.